PMID- 27808488
OWN - NLM
STAT- MEDLINE
DCOM- 20170224
LR  - 20170224
IS  - 1827-1669 (Electronic)
IS  - 0026-4806 (Linking)
VI  - 108
IP  - 2
DP  - 2017 Apr
TI  - Association of HLA-DRB1 gene polymorphisms with hepatocellular carcinoma risk: a 
      meta-analysis.
PG  - 176-184
LID - 10.23736/S0026-4806.16.04571-7 [doi]
AB  - INTRODUCTION: The study aimed to assess the association between human leukocyte 
      antigen (HLA)-DRB1 allele polymorphisms and hepatocellular carcinoma (HCC) 
      susceptibility. EVIDENCE ACQUISITION: Relevant case-control studies on HLA-DRB1 
      allele correlation with HCC risk published between 2000 and 2015 were searched 
      and retrieved in literature database. The odds ratio (OR) with its 95% confidence 
      interval (CI) were employed to calculate the strength of association. Total 16 
      articles including 2208 HCC patients and 3028 relevant controls were finally 
      screened out. EVIDENCE SYNTHESIS: A total of 12 case-control studies including 
      2030 HCC patients and 2817 relevant controls were screened out. Thirteen alleles 
      (HLA-DRB1 *01, *03, *04, *07, *08, *09, *10, *11, *12, *13, *14, *15, and *16) 
      were reported. Overall, we found that HLA-DRB1 *1 and *11 allele polymorphisms 
      were significantly associated with decreased the HCC risk (*1: OR=0.53, 95% CI: 
      0.29-0.96, P=0.04; *11: OR=0.58, 95% CI: 0.38-0.88, P=0.010); while *12 and *14 
      allele polymorphisms were significantly associated with increased the HCC risk 
      (*12: OR=1.49, 95% CI: 1.08-2.07, P=0.02; *14: OR=1.89, 95% CI: 1.27-2.82, 
      P=0.002) in a fixed-effect model. However, other HLA-DRB1 allele polymorphisms 
      were not associated with HCC susceptibility (P>0.05). CONCLUSIONS: HLA-DRB1 *1 
      and *11 allele polymorphisms were protective factors, *12 and *14 allele 
      polymorphisms were risk factors for HCC development. Future large-scale studies 
      with more ethnicities are still needed.
FAU - Liu, Li
AU  - Liu L
AD  - The Second Affiliated Hospital of Nanchang University, Nanchang, China.
FAU - Guo, Wuhua
AU  - Guo W
AD  - The Second Affiliated Hospital of Nanchang University, Nanchang, China.
FAU - Zhang, Jixiang
AU  - Zhang J
AD  - The Second Affiliated Hospital of Nanchang University, Nanchang, China - 
      jxzhang3@163.com.
AD  - Jiangxi Province Key Laboratory of Molecular Medicine, Nanchang, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20161103
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - 0 (HLA-DRB1 Chains)
SB  - IM
MH  - *Alleles
MH  - Carcinoma, Hepatocellular/*genetics
MH  - Case-Control Studies
MH  - Confidence Intervals
MH  - Genetic Predisposition to Disease
MH  - HLA-DRB1 Chains/*genetics
MH  - Humans
MH  - Liver Neoplasms/*genetics
MH  - Odds Ratio
MH  - *Polymorphism, Genetic
MH  - Publication Bias
MH  - Risk
EDAT- 2016/11/04 06:00
MHDA- 2017/02/25 06:00
CRDT- 2016/11/04 06:00
PHST- 2016/11/04 06:00 [pubmed]
PHST- 2017/02/25 06:00 [medline]
PHST- 2016/11/04 06:00 [entrez]
AID - R10Y9999N00A16110301 [pii]
AID - 10.23736/S0026-4806.16.04571-7 [doi]
PST - ppublish
SO  - Minerva Med. 2017 Apr;108(2):176-184. doi: 10.23736/S0026-4806.16.04571-7. Epub 
      2016 Nov 3.